Introducing Vimizim® (elosulfase alfa) enzyme replacement therapy.
COMPLETE PRODUCTION, MOTION GRAPHICS, INTERVIEWS, INFORMATIVE, CORPORATE PROMOTIONAL, VIDEOGRAPHY, PRODUCT LAUNCH
Introducing Vimizim® (elosulfase alfa) from Biomarin® Pharmaceutical
For this opportunity, we partnered with Biomarin Pharmaceutical for the launch of the first and only enzyme (galactosamine [N-acetyl]-6-sulfatase [GALNS]) replacement therapy for those born with Morquio A syndrome (a rare, metabolic genetic disorder which effects bone, cartilage, corneas, skin, and connective tissue). We took on the role of storytellers, where we were honored with the privilege of speaking with several families living with Morquio A syndrome and documented their stories into a short series of testimonial videos.